Field Notes/notes: Pharmacotherapy & Patho & OTC
Hematology
2025.04.26
HematologyIron Deficiency Anemia์ฒ ๊ฒฐํ•์„ฑ ๋นˆํ˜ˆ (IDA: Iron Deficiency Anemia)์ •์˜: ์ฒ ๋ถ„ ๋ถ€์กฑ์œผ๋กœ ์ธํ•œ ํ˜ˆ์ƒ‰์†Œ ํ•ฉ์„ฑ ์ €ํ•˜์ง„๋‹จ: Hb↓, MCV↓ (์†Œ๊ตฌ์„ฑ), ํ˜ˆ์ฒญ Ferritin↓, TIBC↑์›์ธ: ์ถœํ˜ˆ(์œ„์žฅ๊ด€), ์›”๊ฒฝ๊ณผ๋‹ค, ํก์ˆ˜ ์žฅ์• ๐Ÿ’Š ์น˜๋ฃŒ ์š”์•ฝ๊ฒฝ๋กœ ์•ฝ๋ฌผ ๋น„๊ณ ๊ฒฝ๊ตฌFerrous sulfate, Ferrous fumarate1์ผ 1~2ํšŒ, ๊ณต๋ณต ๊ถŒ์žฅ, ๋ณ€๋น„/๊ตฌํ†  ๊ฐ€๋Šฅ์ฃผ์‚ฌIron sucrose, Ferric carboxymaltose๊ฒฝ๊ตฌ ๋ถˆ๋‚ด์„ฑ/์ค‘์ฆ ๋นˆํ˜ˆ ์‹œ ์‚ฌ์šฉ๐Ÿ’ก ๋ชฉํ‘œ Hb: ์—ฌ์„ฑ >12 / ๋‚จ์„ฑ >13๐Ÿ’ก ์น˜๋ฃŒ ํ›„ 3~6๊ฐœ์›” ์œ ์ง€ ํ•„์š”๐Ÿง  ์งˆ๋ณ‘ ์š”์•ฝMegaloblastic Anemia๊ฑฐ๋Œ€์ ์•„๊ตฌ์„ฑ ๋นˆํ˜ˆ (Megaloblastic Anemia)์›์ธ: Vit ..
Field Notes/notes: Pharmacotherapy & Patho & OTC
Opthalmology
2025.04.26
OpthalmologyGlaucoma๋…น๋‚ด์žฅ (Glaucoma)์ •์˜: ์•ˆ์••(IOP) ์ƒ์Šน์œผ๋กœ ์‹œ์‹ ๊ฒฝ ์†์ƒ ๋ฐ ์‹œ์•ผ ๊ฒฐ์† ์œ ๋ฐœ๋ถ„๋ฅ˜๊ฐœ๋ฐฉ๊ฐ ๋…น๋‚ด์žฅ (POAG): ์„œ์„œํžˆ ์ง„ํ–‰, ํ”ํ•จํ์‡„๊ฐ ๋…น๋‚ด์žฅ (ACG): ๊ธ‰์„ฑ, ์•ˆ๊ณผ ์‘๊ธ‰๋ณ‘ํƒœ์ƒ๋ฆฌ: ๋ฐฉ์ˆ˜์˜ ์ƒ์„ฑ-๋ฐฐ์ถœ ๋ถˆ๊ท ํ˜• → ์•ˆ์•• ์ƒ์Šน → ์‹œ์‹ ๊ฒฝ ์†์ƒ๐Ÿ’Š ์•ฝ๋ฌผ์น˜๋ฃŒ ์š”์•ฝ (์•ˆ์•• ๋‚ฎ์ถ”๊ธฐ ๋ชฉ์ )์•ฝ๋ฌผ๊ตฐ ์•ฝ๋ฌผ๋ช… ๊ธฐ์ „ ํŠน์ง• / ๋ถ€์ž‘์šฉProstaglandin ์œ ์‚ฌ์ฒดLatanoprost, Bimatoprost์œ ์ถœ ์ฆ๊ฐ€1์ผ 1ํšŒ, ์ƒ‰์†Œ์นจ์ฐฉ, ์†๋ˆˆ์น ์ฆ๊ฐ€β์ฐจ๋‹จ์ œTimolol์ƒ์„ฑ ๊ฐ์†Œ์ „์‹  ๋ถ€์ž‘์šฉ: ์„œ๋งฅ, ์ฒœ์‹ ํ™˜์ž ๊ธˆ๊ธฐα2-์ž‘์šฉ์ œBrimonidine์ƒ์„ฑ ↓ + ์œ ์ถœ ↑์กธ๋ฆผ, ๊ตฌ๊ฐ• ๊ฑด์กฐCarbonic anhydrase ์–ต์ œ์ œDorzolamide (์ ์•ˆ), Acetazolamide (๊ฒฝ๊ตฌ)์ƒ์„ฑ ๊ฐ์†Œ..
Field Notes/notes: Pharmacotherapy & Patho & OTC
OBGY
2025.04.26
OBGYContraceptionํ”ผ์ž„ (Contraception)์ •์˜: ์ž„์‹ ์„ ์˜ˆ๋ฐฉํ•˜๊ธฐ ์œ„ํ•œ ๋‹ค์–‘ํ•œ ๋ฐฉ๋ฒ•๋ถ„๋ฅ˜ํ˜ธ๋ฅด๋ชฌ ํ”ผ์ž„: ๊ฒฝ๊ตฌํ”ผ์ž„์•ฝ, ํŒจ์น˜, ์ฃผ์‚ฌ์ œ, ์ž๊ถ ๋‚ด ์‹œ์Šคํ…œ(IUS)์žฅ๋ฒฝ ํ”ผ์ž„: ์ฝ˜๋”, ๋‹ค์ด์•„ํ”„๋žจ์˜๊ตฌ ํ”ผ์ž„: ๋‚œ๊ด€ ๊ฒฐ์ฐฐ, ์ •๊ด€ ์ ˆ์ œ๊ธด๊ธ‰ ํ”ผ์ž„: ์„ฑ๊ด€๊ณ„ ํ›„ ๋‹จ๊ธฐ๊ฐ„ ๋‚ด ํ”ผ์ž„๐Ÿ’Š ํ˜ธ๋ฅด๋ชฌ ํ”ผ์ž„ ์š”๋ฒ•์„ฑ๋ถ„: ์—์ŠคํŠธ๋กœ๊ฒ(์ฃผ๋กœ Ethinyl estradiol) + ํ”„๋กœ๊ฒŒ์Šคํ‹ด๋ณต์šฉ๋ฒ•: 21์ผ ๋ณต์šฉ + 7์ผ ํœด์•ฝ / 28์ • ์—ฐ์† ๋ณต์šฉํ˜•ํšจ๊ณผ: ๋ฐฐ๋ž€ ์–ต์ œ, ์ž๊ถ๊ฒฝ๋ถ€ ์ ์•ก ๋ณ€ํ™”์ถ”๊ฐ€ ์žฅ์ : ์ƒ๋ฆฌํ†ต, ์—ฌ๋“œ๋ฆ„ ๊ฐœ์„ , ์ž๊ถ๋‚ด๋ง‰์•”·๋‚œ์†Œ์•” ์˜ˆ๋ฐฉโš ๏ธ ๊ธˆ๊ธฐํ˜ˆ์ „์ฆ ๋ณ‘๋ ฅ, ๊ณ ํ˜ˆ์••, ํก์—ฐ(35์„ธ ์ด์ƒ), ๊ฐ„์งˆํ™˜, ์œ ๋ฐฉ์•”โœ… ํ”„๋กœ๊ฒŒ์Šคํ‹ด ๋‹จ๋…์ œPO (๋ฏธ๋‹ˆํ•„): ์ˆ˜์œ ๋ถ€, ์—์ŠคํŠธ๋กœ๊ฒ ๊ธˆ๊ธฐ ์‹œDMPA ์ฃผ์‚ฌ์ œ (Depo-Provera): 3๊ฐœ์›”๋งˆ๋‹ค ๊ทผ์œก์ฃผ์‚ฌI..
Field Notes/notes: Pharmacotherapy & Patho & OTC
CNS
2025.04.26
CNSMDD์šฐ์šธ์ฆ (Major Depressive Disorder, MDD)์ •์˜: ์ง€์†์ ์ธ ์šฐ์šธ๊ฐ ๋˜๋Š” ํฅ๋ฏธ·์พŒ๋ฝ ์ƒ์‹ค + ๊ธฐํƒ€ ์ฆ์ƒ์ด 2์ฃผ ์ด์ƒ ์ง€์†๋˜๋Š” ์ƒํƒœ์ฆ์ƒ (DSM-5 ๊ธฐ์ค€): 9๊ฐ€์ง€ ์ค‘ 5๊ฐœ ์ด์ƒ, ๊ทธ ์ค‘ ํ•˜๋‚˜๋Š” ๋ฐ˜๋“œ์‹œ โ‘  ๋˜๋Š” โ‘ก ํฌํ•จ์šฐ์šธํ•œ ๊ธฐ๋ถ„ํฅ๋ฏธ·์พŒ๋ฝ ์ƒ์‹ค์ฒด์ค‘/์‹์š• ๋ณ€ํ™”์ˆ˜๋ฉด ๋ณ€ํ™”์ •์‹ ์šด๋™์„ฑ ๋ณ€ํ™”ํ”ผ๋กœ๊ฐ๋ฌด๊ฐ€์น˜๊ฐ/์ฃ„์ฑ…๊ฐ์ง‘์ค‘๋ ฅ ์ €ํ•˜์ž์‚ด ์‚ฌ๊ณ ์ง„๋‹จ: ์ž„์ƒ ํ‰๊ฐ€ (์šฐ์šธ์ฒ™๋„, ์‹ ์ฒด์งˆํ™˜ ๊ฐ๋ณ„ ํฌํ•จ)๐Ÿ’Š ์•ฝ๋ฌผ ์š”๋ฒ• ์š”์•ฝ์•ฝ๋ฌผ ์šฉ๋Ÿ‰ ํŠน์ง•Fluoxetine20–60mg/day๋ฐ˜๊ฐ๊ธฐ ๊น€ → ๊ธˆ๋‹จ์ฆ์ƒ ์ ์ŒSertraline50–200mg/day์œ„์žฅ์žฅ์•  ํ”ํ•จEscitalopram10–20mg/day๋น„๊ต์  ๋ถ€์ž‘์šฉ ์ ์Œ๋ถ€์ž‘์šฉ: ์†Œํ™”๋ถˆ๋Ÿ‰, ์„ฑ๊ธฐ๋Šฅ์žฅ์• , ๋ถˆ์•ˆ, ์ˆ˜๋ฉด์žฅ์•  ๋“ฑ์ž‘์šฉ์‹œ์ž‘: 2–4์ฃผ, ์ตœ๋Œ€ ํšจ๊ณผ๊นŒ์ง€ 6–8์ฃผโœ… ๊ธฐํƒ€ ํ•ญ..
Field Notes/notes: Pharmacotherapy & Patho & OTC
Musculoskeletal
2025.04.26
MusculoskeletalGoutํ†ตํ’ (Gout)์ •์˜: ์š”์‚ฐ(uric acid)์ด ๊ด€์ ˆ์— ์นจ์ฐฉ → ๊ธ‰์„ฑ ์—ผ์ฆ ์œ ๋ฐœ์›์ธ์š”์‚ฐ ์ƒ์„ฑ ์ฆ๊ฐ€: ํ“จ๋ฆฐ ๊ณผ๋‹ค์„ญ์ทจ, ์„ธํฌํŒŒ๊ดด(ํ•ญ์•” ๋“ฑ)์š”์‚ฐ ๋ฐฐ์„ค ๊ฐ์†Œ: ์‹ ๋ถ€์ „, ์ด๋‡จ์ œ์ฆ์ƒ๊ธ‰์„ฑ: ํ•œ์ชฝ ๊ด€์ ˆ(์ฃผ๋กœ ์—„์ง€๋ฐœ๊ฐ€๋ฝ, 1st MTP)์— ๊ทน์‹ฌํ•œ ํ†ต์ฆ, ๋ฐœ์ , ๋ถ€์ข…๋งŒ์„ฑ: ๊ด€์ ˆ ํŒŒ๊ดด, ํ† ํ‘ธ์Šค(tophi) ํ˜•์„ฑ์ง„๋‹จ๊ด€์ ˆ์ฒœ์ž → ์Œ์„ฑ ์ด์ค‘๊ตด์ ˆ์„ฑ ์š”์‚ฐ ๊ฒฐ์ •ํ˜ˆ์ค‘ ์š”์‚ฐ↑ (๋‹จ, ๋ฐœ์ž‘ ์‹œ ์ •์ƒ์ด๊ธฐ๋„ ํ•จ)๐Ÿ’Š ์น˜๋ฃŒ ์š”์•ฝNSAIDs (1์ฐจ): Naproxen, Indomethacin ๋“ฑColchicine: 1.2mg → 0.6mg 1์‹œ๊ฐ„ ํ›„ (ํ•˜๋ฃจ ์ตœ๋Œ€ 1.8mg)๋ถ€์ž‘์šฉ: ์œ„์žฅ์žฅ์• , ์„ค์‚ฌ์Šคํ…Œ๋กœ์ด๋“œ: Prednisolone PO or intra-articular injectionNSAIDs/Colchic..
Field Notes/notes: Pharmacotherapy & Patho & OTC
GI
2025.04.26
GIGERD์œ„์‹๋„์—ญ๋ฅ˜์งˆํ™˜ (GERD: Gastroesophageal Reflux Disease)์ •์˜: ์œ„ ๋‚ด์šฉ๋ฌผ์ด ์‹๋„๋กœ ์—ญ๋ฅ˜ํ•ด ์‹๋„ ์ ๋ง‰ ์†์ƒ ๋˜๋Š” ์ฆ์ƒ ์œ ๋ฐœ์ฆ์ƒ์ „ํ˜•์ : ์†์“ฐ๋ฆผ(heartburn), ์‚ฐ ์—ญ๋ฅ˜(regurgitation)๋น„์ „ํ˜•์ : ๊ธฐ์นจ, ์ธํ›„ํ†ต, ์ฒœ์‹ ์•…ํ™”, ํ‰ํ†ต์ง„๋‹จ์ „ํ˜•์  ์ฆ์ƒ → ์ง„๋‹จ์  PPI ์‹œ๋„๋‚ด์‹œ๊ฒฝ: ์‹๋„์—ผ ์—ฌ๋ถ€ ํ™•์ธ24์‹œ๊ฐ„ pH ๋ชจ๋‹ˆํ„ฐ๋ง: ํ™•์ง„์— ์‚ฌ์šฉ๐Ÿ’Š ์น˜๋ฃŒ ์š”์•ฝ์•ฝ๋ฌผ: Omeprazole, Esomeprazole, Lansoprazole ๋“ฑ์šฉ๋Ÿ‰ ์˜ˆ์‹œ: Omeprazole 20mg qd, Esomeprazole 40mg qd๋ณต์šฉ๋ฒ•: ๊ณต๋ณต ์•„์นจ 30๋ถ„ ์ „๊ธฐ๊ฐ„: 4–8์ฃผ (erosive GERD๋Š” 8์ฃผ ์ด์ƒ)๋ถ€์ž‘์šฉ: ๋‘ํ†ต, ์„ค์‚ฌ, ์ €๋งˆ๊ทธ๋„ค์Š˜ํ˜ˆ์ฆ, Vit B12 ๊ฒฐํ•, ๊ฐ์—ผ ์œ„ํ—˜ (C...
Field Notes/notes: Pharmacotherapy & Patho & OTC
Endocrine
2025.04.26
EndocrineDiabetes๋‹น๋‡จ๋ณ‘ (Diabetes Mellitus)์ •์˜: ์ธ์А๋ฆฐ ๋ถ„๋น„ ๋˜๋Š” ์ž‘์šฉ ์ด์ƒ์œผ๋กœ ๊ณ ํ˜ˆ๋‹น์ด ๋งŒ์„ฑ์ ์œผ๋กœ ์ง€์†๋˜๋Š” ๋Œ€์‚ฌ์งˆํ™˜๋ถ„๋ฅ˜1ํ˜• DM: ์ž๊ฐ€๋ฉด์—ญ์„ฑ, ์ธ์А๋ฆฐ ์ ˆ๋Œ€ ๊ฒฐํ• (์ Š์€ ๋‚˜์ด ๋ฐœ๋ณ‘, ์ผ€ํ†ค์‚ฐ์ฆ ์œ„ํ—˜↑)2ํ˜• DM: ์ธ์А๋ฆฐ ์ €ํ•ญ์„ฑ + ๋ถ„๋น„ ๋ถ€์กฑ (์ค‘์žฅ๋…„, ๋น„๋งŒ ๊ด€๋ จ)์ง„๋‹จ ๊ธฐ์ค€ (1๊ฐœ ์ด์ƒ ํ•ด๋‹น ์‹œ)๊ณต๋ณต ํ˜ˆ๋‹น ≥ 126 mg/dL75g OGTT 2์‹œ๊ฐ„ ํ›„ ≥ 200 mg/dL๋‹นํ™”ํ˜ˆ์ƒ‰์†Œ(HbA1c) ≥ 6.5%์ฆ์ƒ + ๋ฌด์ž‘์œ„ ํ˜ˆ๋‹น ≥ 200 mg/dL๋ชฉํ‘œ์น˜ (์ผ๋ฐ˜ ํ™˜์ž ๊ธฐ์ค€)HbA1c ๊ณต๋ณตํ˜ˆ๋‹น 80–130 mg/dL์‹ํ›„ 2์‹œ๊ฐ„ ํ˜ˆ๋‹น ๐Ÿ’Š ๊ฒฝ๊ตฌํ˜ˆ๋‹น๊ฐ•ํ•˜์ œ ์š”์•ฝMetformin1์ฐจ ์•ฝ์ œ (์ฒด์ค‘์ค‘๋ฆฝ, ์ €ํ˜ˆ๋‹น ์—†์Œ)์šฉ๋Ÿ‰: 500–2000mg/day (๋ถ„ํ•  ๋ณต์šฉ)๋ถ€์ž‘์šฉ: ์œ„์žฅ์žฅ์• , ์ –์‚ฐ์‚ฐ์ฆ (..
Field Notes/notes: Pharmacotherapy & Patho & OTC
Infectious
2025.04.26
InfectiousSummary๊ฐ์—ผ ์˜ˆ๋ฐฉ & ํ•ญ์ƒ์ œ ์„ ํƒ ์š”๋ น1. ๊ฐ€๋Šฅํ•œ ๋ณ‘์›์ฒด ์ถ”์ • (๊ฐ์—ผ ๋ถ€์œ„, ํ™˜์ž ์ƒํƒœ, ์œ ๋ณ‘๊ท  ๊ฐ์•ˆ)2. ํ•ญ๊ท ์ œ ์ŠคํŽ™ํŠธ๋Ÿผ ์ ์ •ํ™” (์ข๊ณ  ์ •ํ™•ํ•˜๊ฒŒ)3. ์•ฝ๋ฌผ ๋™ํƒœ ๊ณ ๋ ค (ํก์ˆ˜, ๋ถ„ํฌ, ๋Œ€์‚ฌ, ๋ฐฐ์„ค)4. ํ™˜์ž ํŠน์„ฑ ๋ฐ˜์˜ (์‹ ๊ธฐ๋Šฅ, ๊ฐ„๊ธฐ๋Šฅ, ์•Œ๋ ˆ๋ฅด๊ธฐ, ์ž„์‹  ๋“ฑ)5. ๊ฐ€๋Šฅํ•œ ๋ณ‘์›๊ท  ๋™์ • ๋ฐ ๊ฐ์ˆ˜์„ฑ ๊ฒฐ๊ณผ ๋ฐ˜์˜ → De-escalationโœ… ํ•ญ์ƒ์ œ ์ ์ ˆ ์‚ฌ์šฉ ์ˆ˜์น™๊ฒฝ๊ตฌ ๊ฐ€๋Šฅ ์‹œ ๋น ๋ฅธ ์ „ํ™˜ (IV → PO)๊ด‘๋ฒ”์œ„ ํ•ญ์ƒ์ œ ์‚ฌ์šฉ ์ตœ์†Œํ™”ํ•ญ์ƒ์ œ ์ค‘๋‹จ ์‹œ์  ์„ค์ • (duration-based vs symptom-based)์ˆ˜์ˆ  ์ „ ์˜ˆ๋ฐฉ์  ํ•ญ์ƒ์ œ: 1ํšŒ ํˆฌ์—ฌ ์›์น™ (์ˆ˜์ˆ  ์ „ 1์‹œ๊ฐ„ ์ด๋‚ด)๐Ÿ’Š ํ•ญ์ƒ์ œ ํˆฌ์—ฌ ๊ธฐ๊ฐ„ ์š”์•ฝ (๋Œ€ํ‘œ ์งˆํ™˜)์งˆํ™˜ ๊ถŒ์žฅ ๊ธฐ๊ฐ„ํ๋ ด (CAP)5–7์ผ์š”๋กœ๊ฐ์—ผ (Cystitis)3–5์ผ์‹ ์šฐ์‹ ์—ผ7..
Field Notes/notes: Pharmacotherapy & Patho & OTC
Renal
2025.04.26
RenalAKI๊ธ‰์„ฑ์‹ ๋ถ€์ „ (Acute Kidney Injury, AKI)์ •์˜: ์ˆ˜์ผ ๋‚ด ๊ธ‰๊ฒฉํ•œ GFR ๊ฐ์†Œ๋กœ ์ธํ•ด BUN, Creatinine ์ƒ์Šน ๋ฐ ์†Œ๋ณ€๋Ÿ‰ ๊ฐ์†Œ์ง„๋‹จ ๊ธฐ์ค€ (KDIGO)Scr 0.3 mg/dL ์ด์ƒ ์ฆ๊ฐ€ (48์‹œ๊ฐ„ ์ด๋‚ด)๋˜๋Š” Scr 1.5๋ฐฐ ์ด์ƒ ์ฆ๊ฐ€ (7์ผ ์ด๋‚ด)๋˜๋Š” ์†Œ๋ณ€๋Ÿ‰ ๋ถ„๋ฅ˜์ „์‹ ์„ฑ(Azotemia): ํ˜ˆ๋ฅ˜์ €ํ•˜ (ํƒˆ์ˆ˜, ์ถœํ˜ˆ, ์‹ฌ๋ถ€์ „)์‹ ์„ฑ: ์‹ ์žฅ ์ž์ฒด ์†์ƒ (์•ฝ๋ฌผ, ์‚ฌ๊ตฌ์ฒด์—ผ, ํ—ˆํ˜ˆ)ํ›„์‹ ์„ฑ: ์š”๋กœํ์ƒ‰ (๊ฒฐ์„, ์ „๋ฆฝ์„ ๋น„๋Œ€ ๋“ฑ)์ฆ์ƒ: ๋ถ€์ข…, ๊ณ ์นผ๋ฅจํ˜ˆ์ฆ, ์š”๋Ÿ‰ ๊ฐ์†Œ, ์˜ค์‹ฌ, ํ”ผ๋กœ๐Ÿ’Š ์น˜๋ฃŒ ์š”์•ฝ์ €ํ˜ˆ์•• ๊ต์ • (์ˆ˜์•ก, ํ˜ˆ์••์•ฝ ์ค‘๋‹จ)์‹ ๋…์„ฑ ์•ฝ๋ฌผ ์ค‘๋‹จ (NSAIDs, ACEi/ARB, Aminoglycoside ๋“ฑ)๊ฐ์—ผ ์‹œ ํ•ญ์ƒ์ œ ์กฐ์ ˆโœ… ์ˆ˜์•ก์š”๋ฒ•์ „์‹ ์„ฑ AKI: ์ˆ˜์•ก ๊ณต๊ธ‰ (Isotonic salin..
Field Notes/notes: Pharmacotherapy & Patho & OTC
Respiratory
2025.04.26
RespiratoryAsthma์ฒœ์‹ (Asthma)์ •์˜: ๊ธฐ๋„ ๊ณผ๋ฏผ์„ฑ๊ณผ ์—ผ์ฆ์— ์˜ํ•œ ๊ฐ€์—ญ์  ๊ธฐ๋„ํ์‡„์„ฑ ํ˜ธํก๊ธฐ ์งˆํ™˜ํŠน์ง•๊ฐ„ํ—์  ๊ธฐ์นจ, ์ฒœ๋ช…(wheezing), ํ‰๋ถ€ ์••๋ฐ•๊ฐ, ํ˜ธํก๊ณค๋ž€์•ผ๊ฐ„·์ƒˆ๋ฒฝ ์ฆ์ƒ ์•…ํ™”, ์šด๋™ ๋˜๋Š” ์•Œ๋ ˆ๋ฅด๊ธฐ ์œ ๋ฐœ ์š”์ธ ์žˆ์Œ์œ ๋ฐœ ์š”์ธ์•Œ๋ ˆ๋ฅด๊ฒ(์ง‘๋จผ์ง€์ง„๋“œ๊ธฐ, ๊ฝƒ๊ฐ€๋ฃจ), ๊ฐ์—ผ, ์ฐฌ ๊ณต๊ธฐ, ์šด๋™, ์ŠคํŠธ๋ ˆ์Šค, ์•„์Šคํ”ผ๋ฆฐ, β์ฐจ๋‹จ์ œ์ง„๋‹จํ๊ธฐ๋Šฅ ๊ฒ€์‚ฌ(FEV1, PEF), β2 ์ž‘์šฉ์ œ ๋ฐ˜์‘์„ฑ(≥12% FEV1 ์ฆ๊ฐ€)์ค‘์ฆ๋„ ๋ถ„๋ฅ˜๊ฐ„ํ—ํ˜•, ๊ฒฝ์ฆ ์ง€์†ํ˜•, ์ค‘๋“ฑ๋„ ์ง€์†ํ˜•, ์ค‘์ฆ ์ง€์†ํ˜•๐Ÿ’Š ์•ฝ๋ฌผ ์š”๋ฒ• ์š”์•ฝ์•ฝ๋ฌผ: Budesonide, Fluticasone, Beclomethasone ๋“ฑ์šฉ๋Ÿ‰:์ €์šฉ๋Ÿ‰: Budesonide 200–400 mcg/day์ค‘๋“ฑ๋Ÿ‰: 400–800 mcg/day๊ณ ์šฉ๋Ÿ‰: >800 mcg/day๋ถ€์ž‘์šฉ: ๊ตฌ๊ฐ•..
Field Notes/notes: Pharmacotherapy & Patho & OTC
Cardiovascular
2025.04.26
CardiovascularSummary์งˆํ™˜ 1์ฐจ ์•ฝ๋ฌผ ์ถ”๊ฐ€/ํŠน์ˆ˜ ์•ฝ๋ฌผ ๋น„๊ณ ๊ณ ํ˜ˆ์••ACEi, ARB, CCB, ThiazideBB (ํŠน์ˆ˜์ƒํ™ฉ), MRA๋ณ‘์šฉ ์š”๋ฒ• ์‹œ ์กฐํ•ฉ ์œ ์˜์‹ฌ๋ถ€์ „ACEi/ARB, BB, MRAARNI, Ivabradine, DigoxinHFrEF ์œ„์ฃผ, ๊ธ‰์„ฑ์‹œ Inotropeํ—ˆํ˜ˆ์„ฑ ์‹ฌ์งˆํ™˜BB, CCB, NitrateRanolazine, Statin์ฆ์ƒ์™„ํ™” + ์˜ˆํ›„๊ฐœ์„  ๋ณ‘ํ–‰ACSDAPT, Heparin, StatinBB, ACEi, FibrinolyticSTEMI ์‹œ PCI or tPA๋ถ€์ •๋งฅClass I–IV ํ•ญ๋ถ€์ •๋งฅ์ œAdenosine, Digoxin์‹ฌ๋ฐฉ์„ธ๋™/์‹ฌ์‹ค๋นˆ๋งฅ ๊ตฌ๋ถ„์ด์ƒ์ง€์งˆํ˜ˆ์ฆStatinEzetimibe, PCSK9, Fibrate๊ณ ์œ„ํ—˜๊ตฐ์€ ๊ณ ๊ฐ•๋„ Statin๋‡Œ์กธ์ค‘Aspirin, Sta..
Field Notes/notes: Pharmacotherapy & Patho & OTC
Oncology
2025.04.26
OncologyBreast CancerBreast Cancer (์œ ๋ฐฉ์•”)์œ ๋ฐฉ์•”์€ ์œ ์„  ์ƒํ”ผ์„ธํฌ์—์„œ ๋ฐœ์ƒํ•˜๋Š” ์•…์„ฑ ์ข…์–‘์œผ๋กœ, ์—ฌ์„ฑ์—๊ฒŒ ๊ฐ€์žฅ ํ”ํ•œ ์•” ์ค‘ ํ•˜๋‚˜๋‹ค. ์—์ŠคํŠธ๋กœ๊ฒ/ํ”„๋กœ๊ฒŒ์Šคํ…Œ๋ก  ์ˆ˜์šฉ์ฒด(HR) ๋ฐ HER2 ๋ฐœํ˜„ ์—ฌ๋ถ€์— ๋”ฐ๋ผ ์•„ํ˜•์ด ๋‚˜๋‰˜๋ฉฐ, ์ด์— ๋”ฐ๋ผ ์น˜๋ฃŒ ์ „๋žต์ด ๋‹ฌ๋ผ์ง„๋‹ค.๐Ÿ” ์ง„๋‹จ ์š”์•ฝ์˜์ƒ ๊ฒ€์‚ฌ: Mammography, Breast ultrasound, MRI์กฐ์ง๊ฒ€์‚ฌ: Core needle biopsy๋ถ„์žํ‘œ์ง€์ž: ER/PR, HER2, Ki-67๋ณ‘๊ธฐ: TNM classification๐Ÿ’Š ์น˜๋ฃŒ ์š”์•ฝ์ดˆ๊ธฐ ์œ ๋ฐฉ์•”์€ ์ˆ˜์ˆ ์ด ์ฃผ ์น˜๋ฃŒ์ด๋ฉฐ, ์ดํ›„ ํ•„์š” ์‹œ ๋ณด์กฐ ํ™”ํ•™์š”๋ฒ•, ๋ฐฉ์‚ฌ์„  ์น˜๋ฃŒ, ํ˜ธ๋ฅด๋ชฌ ์š”๋ฒ•, ํ‘œ์  ์น˜๋ฃŒ๊ฐ€ ๋ณ‘ํ–‰๋œ๋‹ค.HR+ ์œ ๋ฐฉ์•”:ํ๊ฒฝ ์ „: Tamoxifen ๋‹จ๋… ๋˜๋Š” ovarian suppression ..
Field Notes/notes: Clincal & Regulatory & PKPD
์•ฝ๋ฌผ๊ตฌ์กฐ์™€ ์•ฝ๋ฆฌ์  ํŠน์„ฑ
2025.04.26
๐Ÿ“˜ ์•ฝ๋ฌผ ๊ตฌ์กฐ๋ฅผ ํ†ตํ•ด ์•ฝ๋ฆฌ ํŠน์„ฑ ๋น ๋ฅด๊ฒŒ ํŒŒ์•…ํ•˜๋Š” ๋ฒ•๐Ÿงฉ 1๋‹จ๊ณ„: ์•ฝ๋ฌผ์˜ ๊ตฌ์กฐ๋Š” ์–ด๋–ป๊ฒŒ ์•ฝ๋ฆฌ ์ž‘์šฉ๊ณผ ์—ฐ๊ฒฐ๋˜๋Š”๊ฐ€?์•ฝ๋ฌผ ๊ตฌ์กฐ๋Š” ์•ฝ๋ฆฌํ•™์  ํŠน์„ฑ์„ ๊ฒฐ์ •ํ•˜๋Š” ํ•ต์‹ฌ์ด๋‹ค. ๊ตฌ์กฐ ๋‚ด **์ž‘์šฉ๊ธฐ(functional groups)**๋Š” ์ˆ˜์šฉ์ฒด ๊ฒฐํ•ฉ, ๋Œ€์‚ฌ, ์ง€์šฉ์„ฑ/์ˆ˜์šฉ์„ฑ ๋“ฑ์— ์ง์ ‘์ ์ธ ์˜ํ–ฅ์„ ๋ฏธ์นœ๋‹ค.๐Ÿ“Œ ๋Œ€ํ‘œ์ ์ธ ์ž‘์šฉ๊ธฐ์™€ ์˜๋ฏธ์ž‘์šฉ๊ธฐ ์˜๋ฏธ ์•ฝ๋ฆฌ์  ํŠน์„ฑ ์˜ˆ์‹œAromatic ringπ-π stacking ๊ฐ€๋Šฅ, ์ง€์šฉ์„ฑ↑์ˆ˜์šฉ์ฒด ์นœํ™”๋„↑ (NSAIDs, antipsychotics)Amine (๊ธฐ๋ณธ์„ฑ)์—ผ๊ธฐ์„ฑ, ์ด์˜จ๊ฒฐํ•ฉ ๊ฐ€๋ŠฅCNS ์นจํˆฌ, ์ˆ˜์šฉ์ฒด ๊ฒฐํ•ฉ (SSRIs, TCA)Carboxylic acid์‚ฐ์„ฑ, ๋‹จ๋ฐฑ๊ฒฐํ•ฉ↑์—ผ์ฆ๋ถ€์œ„ ๋†๋„↑, NSAIDsHydroxyl (-OH)์ˆ˜์†Œ๊ฒฐํ•ฉ ๊ฐ€๋Šฅ์„ฑ↑์šฉํ•ด๋„↑, β-blockersHalogen (F, C..
Field Notes/notes: Pharmacotherapy & Patho & OTC
๋ณ‘ํƒœ์ƒ๋ฆฌํ•™
2025.04.26
๐Ÿ“˜ ๋ณ‘ํƒœ์ƒ๋ฆฌํ•™ ์š”์•ฝ ์ •๋ฆฌ๐Ÿ“‚ 1. ๋ณ‘ํƒœ์ƒ๋ฆฌํ•™์ด๋ž€?์ •์˜: ์ •์ƒ ์ƒ๋ฆฌ์—์„œ ๋ฒ—์–ด๋‚œ **์งˆ๋ณ‘์˜ ๊ธฐ์ „(๋ณ‘์˜ ์›์ธ ๋ฐ ๋ฐœ์ƒ๊ณผ์ •)**์„ ์„ค๋ช…ํ•˜๋Š” ์˜๊ณผํ•™์˜ ํ•ต์‹ฌ ์˜์—ญ.๋ณ‘ํƒœ์ƒ๋ฆฌํ•™์€ ์˜ํ•™, ์•ฝํ•™, ๊ฐ„ํ˜ธํ•™, ์žฌํ™œ ๋“ฑ ๋ชจ๋“  ํ—ฌ์Šค์ผ€์–ด ์ง๊ตฐ์˜ ๊ธฐ์ดˆ๋ฅผ ์ด๋ฃธ.Patho(๋ณ‘๋ฆฌ) + Physiology(์ƒ๋ฆฌ) = ์งˆ๋ณ‘ ์ƒํƒœ์—์„œ ์ธ์ฒด๊ฐ€ ์–ด๋–ป๊ฒŒ ๋ณ€ํ™”ํ•˜๋Š”์ง€๋ฅผ ์„ค๋ช…์งˆํ™˜์˜ ์›์ธ, ๋ฐœ๋ณ‘ ๋ฉ”์ปค๋‹ˆ์ฆ˜, ์ž„์ƒ ์ฆ์ƒ, ์ง„๋‹จ ๊ธฐ์ค€๊นŒ์ง€ ํฌํ•จ๐Ÿ“‚ 2. ๋ณ‘ํƒœ์ƒ๋ฆฌํ•™ ํ•™์Šต ํ๋ฆ„๋„์ •์ƒ ์ƒ๋ฆฌํ•™ → ์†์ƒ ์š”์ธ ๋ฐœ์ƒ → ํ•ญ์ƒ์„ฑ ๋ถ•๊ดด → ๋ณด์ƒ ์ž‘์šฉ → ์งˆ๋ณ‘์œผ๋กœ ์ง„ํ–‰์งˆ๋ณ‘ ๋ฐœ์ƒ์˜ ํ•ต์‹ฌ ์š”์†Œ:์„ธํฌ ์†์ƒ (์‚ฐํ™” ์ŠคํŠธ๋ ˆ์Šค, ์—ผ์ฆ, ์œ ์ „์ž ๋Œ์—ฐ๋ณ€์ด ๋“ฑ)๋ฉด์—ญ ๋ฐ˜์‘ (๊ณผ์ž‰๋ฐ˜์‘ vs ์–ต์ œ)๋Œ€์‚ฌ ์žฅ์•  (ํ˜ธ๋ฅด๋ชฌ, ์—๋„ˆ์ง€ ๋ถˆ๊ท ํ˜•)๊ฐ์—ผ (๋ฐ”์ด๋Ÿฌ์Šค, ๋ฐ•ํ…Œ๋ฆฌ์•„ ๋“ฑ)๐Ÿ“‚ 3. ์ฃผ์š” ๊ณ„ํ†ต๋ณ„ ๋ณ‘ํƒœ์ƒ๋ฆฌ ์š”..
Field Notes/notes: Clincal & Regulatory & PKPD
PK/PD ๊ธฐ๋ฐ˜ ์ž„์ƒ ์ดˆ๊ธฐ ์šฉ๋Ÿ‰ ์„ค๊ณ„ ํ๋ฆ„๋„
2025.04.26
๐Ÿ’‰ PK/PD ๊ธฐ๋ฐ˜ ์ž„์ƒ ์ดˆ๊ธฐ ์šฉ๋Ÿ‰ ์„ค๊ณ„ ํ๋ฆ„๋„A[๐Ÿ“ ๋น„์ž„์ƒ ์ž๋ฃŒ ์ˆ˜์ง‘] --> B[๐Ÿ”ฌ PK ๋ถ„์„ (ADME ํ‰๊ฐ€)] B --> C[๐Ÿงฌ PD ๋ถ„์„ (์•ฝ๋ฆฌํšจ๊ณผ ์ง€ํ‘œ ํ™•์ธ)] C --> D[๐Ÿ“ˆ PK/PD ๋ชจ๋ธ๋ง ๋ฐ ํŒŒ๋ผ๋ฏธํ„ฐ ์ถ”์ •(Emax, EC50 ๋“ฑ)] D --> E[๐Ÿง  ์‚ฌ๋žŒ ๋Œ€์ƒ ์•ฝํšจ ๋†๋„ ์˜ˆ์ธก (exposure-response)] E --> F[MABEL ๋˜๋Š” PK ๊ธฐ๋ฐ˜ ์šฉ๋Ÿ‰ ์‚ฐ์ถœ(Target exposure ๊ธฐ๋ฐ˜)] F --> G[๐Ÿ” ์•ˆ์ „๊ณ„์ˆ˜ ์ ์šฉ (10–100๋ฐฐ)] G --> H[๐Ÿงช ์ž„์ƒ 1์ƒ ์‹œ์ž‘ ์šฉ๋Ÿ‰ ๊ฒฐ์ •] H --> I[๐Ÿ“‰ Dose Escalation Plan ์„ค๊ณ„ (SAD/MAD)]๐Ÿ“Œ ๊ฐ ๋‹จ๊ณ„ ์„ค๋ช… ์š”์•ฝ๋‹จ๊ณ„ ์„ค๋ช…๋น„์ž„์ƒ ์ž๋ฃŒ ์ˆ˜์ง‘๋™๋ฌผ PK/PD, ๋…์„ฑ, ์•ฝํšจ ๋“ฑ ํ™•๋ณดPK ๋ถ„์„..
Field Notes/notes: Clincal & Regulatory & PKPD
MABEL (Minimum Anticipated Biological Effect Level) ๊ธฐ๋ฐ˜ ์šฉ๋Ÿ‰ ์„ค์ •
2025.04.26
๐Ÿงฌ MABEL (Minimum Anticipated Biological Effect Level) ๊ธฐ๋ฐ˜ ์šฉ๋Ÿ‰ ์„ค์ •๐Ÿ“Œ MABEL์ด๋ž€?์•ฝ๋ฆฌํ•™์  ๋ฐ˜์‘์ด ์ตœ์ดˆ๋กœ ๊ธฐ๋Œ€๋˜๋Š” ์ตœ์†Œ ์šฉ๋Ÿ‰= ๋น„๋…์„ฑ ๊ธฐ์ค€์ด ์•„๋‹Œ "ํšจ๊ณผ" ๊ธฐ์ค€์œผ๋กœ ๊ณ„์‚ฐ๋œ ์ดˆ๊ธฐ์šฉ๋Ÿ‰๋ฉด์—ญ์กฐ์ ˆ์ œ, ๋‹จ์ผํด๋ก ํ•ญ์ฒด, ์„ธํฌ/์œ ์ „์ž ์น˜๋ฃŒ์ œ์ฒ˜๋Ÿผ๊ณ ์œ„ํ—˜ ์ƒ๋ฌผ์˜์•ฝํ’ˆ์˜ ์ž„์ƒ 1์ƒ ์ดˆ๊ธฐ ์šฉ๋Ÿ‰ ์„ค๊ณ„์— ํ•„์ˆ˜.โš™๏ธ MABEL ๊ณ„์‚ฐ ํ๋ฆ„in vitro ์•ฝ๋ฆฌ ํ™œ์„ฑ ๋ฐ์ดํ„ฐ์ˆ˜์šฉ์ฒด ๊ฒฐํ•ฉ์นœํ™”๋„ (KD)ECโ‚…โ‚€, ICโ‚…โ‚€ (์„ธํฌ ๊ธฐ์ค€)target cell์˜ ์ˆ˜์šฉ์ฒด ๋ฐœํ˜„ ์ˆ˜์ค€in vivo ์ตœ์†Œ ์œ ํšจ ์šฉ๋Ÿ‰๋™๋ฌผ๋ชจ๋ธ PK/PD (์˜ˆ: ์ƒ์ฒด์ง€ํ‘œ, ์ข…์–‘ ํฌ๊ธฐ ๊ฐ์†Œ)PD Marker ๊ธฐ๋ฐ˜ Human Effect ์ถ”์ •ํ˜ˆ์ค‘ ๋†๋„ vs ํšจ๊ณผ ๊ณก์„ PBPK/PK ๋ชจ๋ธ ์‹œ๋ฎฌ๋ ˆ์ด์…˜์‚ฌ๋žŒ์—์„œ ์˜ˆ์ธก ๋†๋„ ์ถ”์ •์ตœ๋Œ€ ํƒ€๊นƒ ์ ์œ ์œจ ..
Field Notes/notes: Clincal & Regulatory & PKPD
NOAEL ๊ธฐ๋ฐ˜ ์ž„์ƒ ์„ค๊ณ„
2025.04.26
๐Ÿงฌ NOAEL ๊ธฐ๋ฐ˜ ์ž„์ƒ ์„ค๊ณ„๐Ÿ“Œ NOAEL์ด๋ž€?No Observed Adverse Effect Level= ํ†ต๊ณ„์ /์ƒ๋ฌผํ•™์ ์œผ๋กœ ์œ ์˜๋ฏธํ•œ ๋ถ€์ž‘์šฉ์ด ๊ด€์ฐฐ๋˜์ง€ ์•Š๋Š” ์ตœ๋Œ€ ์šฉ๋Ÿ‰์ „์ž„์ƒ(๋™๋ฌผ์‹คํ—˜)์—์„œ ์–ป์€ ์•ˆ์ „ ์šฉ๋Ÿ‰์˜ ๊ธฐ์ค€์ดˆ๊ธฐ ์ž„์ƒ(1์ƒ) ์šฉ๋Ÿ‰ ์„ค์ •์˜ ํ•ต์‹ฌ ์ง€ํ‘œ๐Ÿ“ 1์ƒ ์šฉ๋Ÿ‰ ์„ค๊ณ„ ๊ธฐ๋ณธ ํ๋ฆ„๋™๋ฌผ์‹คํ—˜์—์„œ NOAEL ์‚ฐ์ถœ (๋ณดํ†ต ๋งˆ์šฐ์Šค, ๊ฐœ, ์›์ˆญ์ด ๋“ฑ)HED (Human Equivalent Dose) ๊ณ„์‚ฐ → NOAEL × (Km ๋™๋ฌผ / Km ์ธ๊ฐ„)์•ˆ์ „๊ณ„์ˆ˜(Safety factor) ์ ์šฉ → ๋ณดํ†ต 10 (๋ฉด์—ญ์กฐ์ ˆ์ œ๋‚˜ ๊ณ ์œ„ํ—˜ ๋ฌผ์งˆ์€ 50~100)MRSD (Maximum Recommended Starting Dose) ์„ค์ •๐Ÿ‘‰ ์ด๊ฒƒ์ด ์ž„์ƒ 1์ƒ ์‹œ์ž‘ ์šฉ๋Ÿ‰โš ๏ธ [์‚ฌ๋ก€] TGN1412 ์ž„์ƒ 1์ƒ ์‚ฌ๊ณ  (2006, ์˜๊ตญ..
Field Notes/notes: Clincal & Regulatory & PKPD
Pharmacokinetics ์‹ค๋ฌด ์ ์šฉ & ํŒŒ๋ผ๋ฏธํ„ฐ ๊ณต์‹
2025.04.26
โš™๏ธ Pharmacokinetics ์‹ค๋ฌด ์ ์šฉ & ํŒŒ๋ผ๋ฏธํ„ฐ ๊ณต์‹๐Ÿงฎ ํ•ต์‹ฌ ํŒŒ๋ผ๋ฏธํ„ฐ ๊ณต์‹ํŒŒ๋ผ๋ฏธํ„ฐ ๊ณต์‹ ์˜๋ฏธ ๋ฐ ์„ค๋ช…Bioavailability (F)F = (AUC_PO / AUC_IV) × (Dose_IV / Dose_PO)๊ฒฝ๊ตฌ ๋Œ€๋น„ ์ •๋งฅํˆฌ์—ฌ ๊ธฐ์ค€ ์ƒ์ฒด์ด์šฉ๋ฅ  (%)Volume of Distribution (Vd)Vd = Dose / Cโ‚€์•ฝ๋ฌผ์ด ์–ผ๋งˆ๋‚˜ ๋„“๊ฒŒ ํผ์กŒ๋Š”์ง€ (L/kg ๋“ฑ)Clearance (Cl)Cl = (F × Dose) / AUCCl = Vd × Ke๋‹จ์œ„ ์‹œ๊ฐ„๋‹น ํ˜ˆ์•ก์—์„œ ์•ฝ๋ฌผ์ด ์ œ๊ฑฐ๋˜๋Š” ์†๋„Elimination rate constant (Ke)Ke = Cl / Vd์ œ๊ฑฐ ์†๋„ (1/h ๋“ฑ), ๋กœ๊ทธ์„ ํ˜• ๊ฐ์†Œ์œจHalf-life (t½)t½ = 0.693 / Keํ˜ˆ์ค‘ ๋†๋„๊ฐ€ ์ ˆ๋ฐ˜์œผ๋กœ ๋–จ์–ด์ง€๋Š” ์‹œ๊ฐ„AU..
Field Notes/notes: Clincal & Regulatory & PKPD
์ „์ž„์ƒ์—์„œ ์ž„์ƒ ์šฉ๋Ÿ‰ ์ „ํ™˜
2025.04.26
๐Ÿงฌ ์ „์ž„์ƒ → ์ž„์ƒ ์šฉ๋Ÿ‰ ์ „ํ™˜๐Ÿ“Œ ๊ธฐ๋ณธ ๊ฐœ๋…: HED (Human Equivalent Dose)HED (mg/kg) = ๋™๋ฌผ์šฉ๋Ÿ‰ (mg/kg) × (K๋™๋ฌผ / K์ธ๊ฐ„)์—ฌ๊ธฐ์„œ K๋Š” ์ฒดํ‘œ๋ฉด์  ๋ณ€ํ™˜๊ณ„์ˆ˜ (BSA conversion factor)์ฒด์ค‘์ด ๊ฐ™๋”๋ผ๋„ ๋Œ€์‚ฌ์œจ๊ณผ ์ฒดํ‘œ๋ฉด์ ์ด ๋‹ค๋ฅด๊ธฐ ๋•Œ๋ฌธ์— ๋‹จ์ˆœ ์ฒด์ค‘๋น„๊ฐ€ ์•„๋‹Œ BSA ๊ธฐ์ค€์œผ๋กœ ์กฐ์ •๐Ÿงฎ K๊ฐ’ (BSA Conversion Factor)์ข… ํ‰๊ท  ์ฒด์ค‘ (kg) Km (K ๊ฐ’)๋งˆ์šฐ์Šค (Mouse)0.023๋žซ (Rat)0.156ํ† ๋ผ (Rabbit)1.812๊ฐœ (Dog)1020์›์ˆญ์ด (Monkey)312์‚ฌ๋žŒ (Human)6037โœ… ์‹ค๋ฌด ๊ณต์‹ ์˜ˆ์‹œ๐Ÿญ ๋งˆ์šฐ์Šค์—์„œ HED๋กœ ๋ณ€ํ™˜๋งˆ์šฐ์Šค์—์„œ 50 mg/kg์˜ ํšจ๊ณผ → ์ธ๊ฐ„์—์„œ๋Š”?HED = 50 × (3 / 37) ≈ 4.05 ..
Field Notes/notes: Clincal & Regulatory & PKPD
Pharmacokinetics (์•ฝ๋ฌผ๋™ํƒœํ•™)
2025.04.26
๐Ÿ’Š Pharmacokinetics (์•ฝ๋ฌผ๋™ํƒœํ•™)๐Ÿ“˜ ๊ฐœ์š”์•ฝ๋ฌผ๋™ํƒœํ•™์€ ์ฒด๋‚ด์—์„œ ์•ฝ๋ฌผ์˜ ํก์ˆ˜, ๋ถ„ํฌ, ๋Œ€์‚ฌ, ๋ฐฐ์„ค ๊ณผ์ •์„ ์ˆ˜์น˜ํ™”ํ•˜๊ณ  ์„ค๋ช…ํ•˜๋Š” ํ•™๋ฌธ.ํ•ต์‹ฌ ์•ฝ์–ด: ADMEAbsorption (ํก์ˆ˜)Distribution (๋ถ„ํฌ)Metabolism (๋Œ€์‚ฌ)Excretion (๋ฐฐ์„ค)๐Ÿ“Œ 1. Absorption (ํก์ˆ˜)ํ•ญ๋ชฉ ์„ค๋ช…์ •์˜ํˆฌ์—ฌ๋œ ์•ฝ๋ฌผ์ด ํ˜ˆ๋ฅ˜๋กœ ๋“ค์–ด๊ฐ€๋Š” ๊ณผ์ •์ฃผ์š” ๊ฒฝ๋กœ๊ฒฝ๊ตฌ, ํ”ผํ•˜, ๊ทผ์œก, ์ •๋งฅ ๋“ฑ์˜ํ–ฅ ์š”์ธpH, ์ง€์šฉ์„ฑ, ๋ถ„์žํฌ๊ธฐ, ์Œ์‹๋ฌผ, ํšจ์†Œ๊ด€๋ จ ๊ฐœ๋…F (์ƒ์ฒด์ด์šฉ๋ฅ ): ๊ฒฝ๊ตฌํˆฌ์—ฌ ํ›„ ํ˜ˆ์ค‘ ๋„๋‹ฌ ๋น„์œจ (IV๋Š” 100%)๐Ÿ“Œ 2. Distribution (๋ถ„ํฌ)ํ•ญ๋ชฉ ์„ค๋ช…์ •์˜ํ˜ˆ๋ฅ˜์—์„œ ์กฐ์ง์œผ๋กœ ์•ฝ๋ฌผ์ด ํผ์ง€๋Š” ๊ณผ์ •์˜ํ–ฅ ์š”์ธํ˜ˆ๋ฅ˜๋Ÿ‰, ๋ชจ์„ธํ˜ˆ๊ด€ ํˆฌ๊ณผ์„ฑ, ์กฐ์ง ๊ฒฐํ•ฉ๋ ฅ, ๋‹จ๋ฐฑ๊ฒฐํ•ฉ๋ฅ ๊ด€๋ จ ์ง€ํ‘œVd (๋ถ„ํฌ์šฉ์ ): ์•ฝ๋ฌผ์ด ์ „์ฒด ์ฒด์•ก..